Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath

Parkinson's Disease Clinical Trial

Official title:

Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01246336
• Other study ID #: RMB09-0196
• Status: Completed
• Phase: N/A
• First received: November 21, 2010
• Last updated: October 30, 2017
• Start date: August 2009
• Est. completion date: January 2012

Study information

• Verified date: October 2017
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Patients with Parkinsonism

Exclusion Criteria:

• Severe dementia

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease
• Parkinsonian Disorders
• Parkinsonism

Intervention

Other:
• collection of exhaled breath
no intervention

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Rambam Health Care Campus	Technion, Israel Institute of Technology

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nanosensory detection	analyze combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)	immediate